Cargando…
P854: HEXABODY-CD38 INDUCES TROGOCYTOSIS AND EFFECTIVELY INDUCES COMPLEMENT-MEDIATED TUMOR CELL LYSIS AFTER TREATMENT WITH DARATUMUMAB OR ISATUXIMAB IN VITRO
Autores principales: | Hiemstra, I. H., Santegoets, K., Janmaat, M. L., Ten Hagen, W., Van Dooremalen, S., De Goeij, B. E., Bosgra, S., Sasser, A. K., Breij, E. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431333/ http://dx.doi.org/10.1097/01.HS9.0000846296.62306.db |
Ejemplares similares
-
P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB
por: Hiemstra, Ida H., et al.
Publicado: (2023) -
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
por: Hiemstra, Ida H., et al.
Publicado: (2023) -
Isatuximab in the Treatment of Multiple Myeloma: A Review and
Comparison With Daratumumab
por: Shen, Fei, et al.
Publicado: (2022) -
Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018) -
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
por: Mikhael, Joseph, et al.
Publicado: (2021)